Xin Lang Cai Jing·2026-02-10 23:04Core Viewpoint - The first prescription of the innovative drug "Sitagliptin Malate Tablets" was issued in Shanghai, marking a significant milestone for Shanghai Pharmaceutical Group and the treatment of primary hypertension [1][3]. Group 1: Drug Overview - "Sitagliptin Malate Tablets" is a first-class innovative drug developed by Shanghai Pharmaceutical Group, representing a new generation of oral non-peptide renin inhibitors [1][6]. - The drug is primarily used for treating primary hypertension, which accounts for over 90% of hypertension cases, as opposed to secondary hypertension caused by identifiable diseases [3][4]. Group 2: Clinical Efficacy - Clinical evidence indicates that the drug can effectively reduce systolic blood pressure by 10-15 mmHg and diastolic blood pressure by 5-10 mmHg, with effects observable from the first day of use [3][4]. - The approval of the drug was based on a rigorously designed Phase III clinical trial led by Professor Ma Changsheng, involving nearly 40 top cardiovascular clinical centers across China [4]. Group 3: Strategic Initiatives - The Pudong New Area has implemented a "3F" strategy (First-in-Class, First-in-China, First-in-Human) to expedite the clinical application of innovative drugs, with the health commission prioritizing the inclusion of this drug in the recommended directory [6]. - The successful launch of this drug reinforces the confidence of Shanghai Pharmaceutical's R&D team in future innovative drug development, supported by ongoing optimization of the biopharmaceutical industry ecosystem in Pudong [6].